Ozlem Yilmaz

Dr. Ozlem Yilmaz

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Allergologia et Immunopathologia
Verified
Journal Article
Closed access
IKI.H.E. Karagol
I.H.E. Karagol
ABA. Bakirtas
A. Bakirtas
OYOzlem Yilmaz
Ozlem Yilmaz
ETErdem Topal
Erdem Topal
AKA. Kucukcongar
A. Kucukcongar
ITI. Turktas
I. Turktas

1 March 2019 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
OYOzlem Yilmaz
Ozlem Yilmaz
BABasar Aykent
Basar Aykent
PKPinar Kucukdagli
Pinar Kucukdagli
CTCemil Tascioglu
Cemil Tascioglu
Gülistan BahatGülistan Bahat
Gülistan Bahat

2 February 2026 in Metabolic Syndrome and Related Disorders
Verified
Journal Article
Closed access
OYOzlem Yilmaz
Ozlem Yilmaz
CICemile Idiz
Cemile Idiz
CKCihan Kilic
Cihan Kilic
SGSena Gurkas
Sena Gurkas
PKPinar Kucukdaglı
Pinar Kucukdaglı
MKMehmet Akif Karan
Mehmet Akif Karan
Background: Sarcopenic obesity (SO), defined as the coexistence of low muscle mass and function and excessive fat mass, is increasingly recognized as a health concern in older individuals with diabetes. Despite its clinical importance, SO often remains undiagnosed in outpatient settings due to complex diagnostic requirements. Objective: This study aimed to investigate the risk of SO using simple screening tools, namely the SARC-F questionnaire and handgrip strength (HGS), and to identify associated clinical, functional, and metabolic factors in diabetic patients aged 50 and older. Methods: A cross-sectional analysis was conducted with 276 diabetic outpatients. Risk of SO was defined based on a body mass index of 30 kg/m² or more, combined with either a SARC-F score of 4 or above or low HGS values (below 35 kg for men and 20 kg for women). Data on comorbidities, functionality, falls, depression, and metabolic control were collected. Results: The prevalence of SO risk was 16.2% with HGS and 8.7% with SARC-F. Falls, depressive symptoms, and reduced quality of life were associated with SARC-F-based SO, while hypertension, elevated HbA1c, and lower quality of life were linked to HGS-based SO. Conclusion: Simple screening methods can help identify SO risk in diabetic outpatients and support timely clinical decision-making.

14 November 2018 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
OYOzlem Yilmaz
Ozlem Yilmaz
BABasar Aykent
Basar Aykent
Gülistan BahatGülistan Bahat
Gülistan Bahat

18 May 2026
Verified
Journal Article
Closed access
FSFeride Sevilmis
Feride Sevilmis
SASevda Averi
Sevda Averi
HAHanife Usta Atmaca
Hanife Usta Atmaca
OYOzlem Yilmaz
Ozlem Yilmaz

1 January 2020 in Clinical Interventions in Aging
Verified
Journal Article
Open access
PDF file
OYOzlem Yilmaz
Ozlem Yilmaz
Gülistan BahatGülistan Bahat
Gülistan Bahat
Important Points to Consider During Practical Application and in the Validation Studies of SARC-F Tool to Screen Sarcopenia [Letter]